Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of $0.32, $0.47 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.